日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Complete genome sequences of Vibrio species, degraders of sulfated polysaccharide ulvan extracted from a green algae Ulva ohnoi

弧菌属(Vibrio)的完整基因组序列,该属细菌能够降解从绿藻大野浒苔(Ulva ohnoi)中提取的硫酸多糖浒苔素。

Zhafirah, Nur Athiqah; Hiraoka, Masanori; Satoh, Miho; Mukrimin, Mukrimin; Millang, Syamsuddin; Ohnishi, Kouhei

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

FGFR2 改变对接受肝内胆管癌全身治疗患者的总生存期和无进展生存期的影响

Abou-Alfa, Ghassan K; Bibeau, Kristen; Schultz, Nikolaus; Yaqubie, Amin; Millang, Brittanie; Ren, Haobo; Féliz, Luis

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

一线使用帕博利珠单抗联合曲妥珠单抗治疗HER2阳性食管癌、胃癌或胃食管交界处癌:一项开放标签、单臂、II期试验

Janjigian, Yelena Y; Maron, Steven B; Chatila, Walid K; Millang, Brittanie; Chavan, Shweta S; Alterman, Carly; Chou, Joanne F; Segal, Michal F; Simmons, Marc Z; Momtaz, Parisa; Shcherba, Marina; Ku, Geoffrey Y; Zervoudakis, Alice; Won, Elizabeth S; Kelsen, David P; Ilson, David H; Nagy, Rebecca J; Lanman, Richard B; Ptashkin, Ryan N; Donoghue, Mark T A; Capanu, Marinela; Taylor, Barry S; Solit, David B; Schultz, Nikolaus; Hechtman, Jaclyn F

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

索拉非尼联合多柔比星治疗索拉非尼治疗后疾病进展的晚期肝细胞癌患者的II期试验

El Dika, Imane; Capanu, Marinela; Chou, Joanne F; Harding, James J; Ly, Michele; Hrabovsky, Anna D; Do, Richard K G; Shia, Jinru; Millang, Brittanie; Ma, Jennifer; O'Reilly, Eileen M; Abou-Alfa, Ghassan K

Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma

贝伐珠单抗联合术前放化疗治疗食管腺癌的II期研究

Ku, Geoffrey Y; Bains, Manjit S; Park, Do Joong; Janjigian, Yelena Y; Rusch, Valerie W; Rizk, Nabil P; Yoon, Sam S; Millang, Brittanie; Capanu, Marinela; Goodman, Karyn A; Ilson, David H